Fine mapping and candidate gene analyses of pulmonary adenoma resistance 1, a major genetic determinant of mouse lung adenoma resistance

Cancer Research

Volumn 67, Issue 6, 2007, Pages 2508-2516

  Wang, Min ^a   Zhang, Zhongqiu ^a   Zhang, Zhuo ^a   Vikis, Haris ^a   Yan, Ying ^a   Wang, Yian ^a   You, Ming ^a  

^a MO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A J MOUSE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE LOCUS; GENE MAPPING; GENETIC ANALYSIS; GENETIC MARKER; GENETIC RESISTANCE; GENETIC SCREENING; HOX GENE; LUNG ADENOMA; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PULMONARY ADENOMA RESISTANCE 1; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; TOB1 GENE; TUMOR SUPPRESSOR GENE;

ADENOMA; ANIMALS; CARRIER PROTEINS; CHROMOSOME MAPPING; FEMALE; GENES, TUMOR SUPPRESSOR; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED A; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI;

EID: 34047274647     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3157     Document Type: Article

References (46)

1. American Cancer Society. Cancer Statistics 2005.
2. Sellers TA, Bailey-Wilson JE, Elston RC, et al. Evidence for mendelian inheritance in the pathogenesis of lung cancer. J Natl Cancer Inst 1990;82:1272-9.
3. Sellers TA, Potter JD, Folsom AR. Association of incident lung cancer with family history of female reproductive cancers: the Iowa Women's Health Study. Genet Epidemiol 1991;8:199-208.
4. Sellers TA, Elston RC, Atwood LD, Rothschild H. Lung cancer histologic type and family history of cancer. Cancer (Phila) 1992;69:86-91.
5. Rudier HW. Genetic predisposition to the toxic effects of chemicals. In: Grandjean P, editor. Ecogenetics. New York: Chapman & Hall; 1991. p. 205-16.
6. Malkinson AM. The genetic basis of susceptibility to lung tumors in mice. Toxicology 1989;54:241-71.
7. Demant P. Cancer susceptibility in the mouse: genetics, biology, and implications for human cancer. Nat Rev Genet 2003;4:721-34.
8. Fijneman RJ, de Vries SS, Jansen RC, Demant P. Complex interactions of new quantitative trait loci, Sluc1, Sluc2, Sluc3, and Sluc4, that influence the susceptibility to lung cancer in the mouse. Nat Genet 1996;14:465-7.
9. Gariboldi M, Manenti G, Canzian F, et al. A major susceptibility locus to murine lung carcinogenesis maps on chromosome 6. Nat Genet 1993;3:132-6.
10. Herzog CR, Lubet RA, You M. Genetic alterations in mouse lung tumors: implications for cancer chemoprevention. J Cell Biochem Suppl 1997;28-29:49-63.
11. Manenti G, Gariboldi M, Elango R, et al. Genetic mapping of a pulmonary adenoma resistance (Par1) in mouse. Nat Genet 1996;12:455-7.
12. Pataer A, Nishimura M, Kamoto T, Ichioka K, Sato M, Hiai H. Genetic resistance to urethan-induced pulmonary adenomas in SMXA recombinant inbred mouse strains. Cancer Res 1997;57:2904-8.
13. Markel P. Theoretical and empirical issues for marker-assisted breeding of congenic mouse strains. Nat Genet 1997;17:280-4.
14. Yoshida Y, Nakamura T, Komoda M, et al. Mice lacking a transcriptional corepressor Tob are predisposed to cancer. Genes Dev 2003;7:1201-6.
15. Sato T, Saito H, Swensen J, et al. The human prohibitin gene located on chromosome 17q21 is mutated in sporadic breast cancer. Cancer Res 1992;52:1643-6.
16. Matsuda S, Kawamura-Tsuzuku J, Ohsugi M, et al. Tob, a novel protein that interacts with p185erbB2, is associated with anti-proliferative activity. Oncogene 1996;12:705-3.
17. Suzuki T, K-Tsuzuku J, Ajima R, Nakamura T, Yoshida Y, Yamamoto T. Phosphorylation of three regulatory serines of Tob by Erk1 and Erk2 is required for Ras-mediated cell proliferation and transformation. Genes Dev 2002;16:1356-70.
18. Iwanaga K, Sueoka N, Sato A, et al. Alteration of expression or phosphorylation status of tob, a novel tumor suppressor gene product, is an early event in lung cancer. Cancer Lett 2003;202:71-9.
19. Zhang Z, Futamura M, Vikis HG, et al. Positional cloning of the major quantitative trait locus underlying lung tumor susceptibility in mice. Proc Natl Acad Sci U S A 2003;100:12642-7.
20. Nagai Y, Kojima T, Muro Y, et al. Identification of a novel nuclear speckle-type protein, SPOP. FEBS Lett 1997;418:23-6.
21. Zapata JM, Pawlowski K, Haas E, Ware CF, Godzik A, Reed JC. A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains. J Biol Chem 2001;276:24242-52.
22. Takahashi I, Kameoka Y, Hashimoto K. MacroH2A1.2 binds the nuclear protein Spop. Biochim Biophys Acta 2002;1591:63-8.
23. Iizuka M, Stillman B. Histone acetyltransferase HBO1 interacts with the ORC1 subunit of the human initiator protein. J Biol Chem 1999;274:23027-34.
24. Burke TW, Cook JG, Asano M, Nevins JR. Replication factors MCM2 and ORC1 interact with the histone acetyltransferase HBO1. J Biol Chem 2001; 276:15397-408.
25. Sharma M, Zarnegar M, Li X, Lim B, Sun Z. Androgen receptor interacts with a novel MYST protein, HBO1. J Biol Chem 2000;275:35200-8.
26. Korotchkina LG, Sidhu S, Patel MS. Characterization of testis-specific isoenzyme of human pyruvate dehydrogenase. J Biol Chem 2006;281:9688-96.
27. Gotting C, Kuhn J, Brinkmann T, Kleesiek K. Xylosylation of alternatively spliced isoforms of Alzheimer APP by xylosyltransferase. J Prot Chem 1998;17: 295-302.
28. Johnson D, Lanahan A, Buck CR, et al. Expression and structure of the human NGF receptor. Cell 1986;47: 545-54.
29. Ricci A, Felici L, Mariotta S, et al. Neurotrophin and neurotrophin receptor protein expression in the human lung. Am J Respir Cell Mol Biol 2004;1:12-9.
30. Tamura RN, Cooper HM, Collo G, Quaranta V. Cell type-specific integrin variants with alternative a chain cytoplasmic domains. Proc Natl Acad Sci U S A 2001;88: 10183-7.
31. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
32. 1-integrins in cervical cancer. Am J Obstet Gynecol 1995;173:808-13.
33. 3 integrin in a rhabdomyosarcoma cell line. Cell Commun Adhes 1996;4:41-52.
34. Seewaldt VL, Mrozek K, Sigle R, et al. Suppression of p53 function in normal human mammary epithelial cells increases sensitivity to extracellular matrix-induced apoptosis. J Cell Biol 2001;155:471-86.
35. 3 expression as a factor of poor prognosis of patients with adenocarcinoma of the lung. J Clin Oncol 1998;16: 1060-7.
36. 3 expression as a prognostic factor in colon cancer: association with MRP-1/CD9 and KAI1/CD82. Int J Cancer 2002;97:518-25.
37. 1 integrin with the altered cell: environmental interactions and enhanced soft agar cloning ability of c-myc-overexpressing small cell lung cancer cells. Cancer Res 1998;58: 5537-45.
38. Sasajima H, Nakagawa K, Yokosawa H. Antiproliferative proteins of the BTG/Tob family are degraded by the ubiquitin-proteasome system. Eur J Biochem 2002; 269:3596-604.
39. Kawamura-Tsuzuku J, Suzuki T, Yoshida Y, Yamamoto T. Nuclear localization of Tob is important for regulation of its antiproliferative activity. Oncogene 2004;23:6630-8.
40. Garcia-Patino E, Gomendio B, Lleonart M, et al. Loss of heterozygosity in the region including the BRCA1 gene on 17q in colon cancer. Cancer Genet Cytogenet 1998;104:119-23.
41. Cropp CS, Nevanlinna HA, Pyrhonen S, et al. Evidence for involvement of BRCA1 in sporadic breast carcinomas. Cancer Res 1994;54:2548-51.
42. Acevedo CM, Henriquez M, Emmert-Buck MR, Chuaqui RF. Loss of heterozygosity on chromosome arms 3p and 6q in microdissected adenocarcinomas of the uterine cervix and adenocarcinoma in situ. Cancer 2002;94:793-802.
43. Sirchia SM, Sironi E, Grati FR, et al. Losses of heterozygosity in endometrial adenocarcinomas: positive correlations with histopathological parameters. Cancer Genet Cytogenet 2000;21:156-62.
44. Huang LW, Garrett AP, Schorge JO, et al. Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum. Am J Clin Pathol 2000;114:93-9.
45. Shiina H, Breault JE, Basset WW, et al. Functional loss of the γ-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res 2005;65: 2130-8.
46. Abujiang P, Mori TJ, Takahashi T, et al. Loss of heterozygosity (LOH) at 17q and 14q in human lung cancers. Oncogene 1998;7:3029-33.